The importance of Src signaling in sarcoma (review)

Oncology Letters

Volumn 10, Issue 1, 2015, Pages 17-22

  Chen, Quanchi ^a   Zhou, Zifei ^a   Shan, Liancheng ^a   Zeng, Hui ^a   Hua, Yingqi ^a   Cai, Zhengdong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; Pharmaceutical target; Sarcoma; Src kinase

Indexed keywords

BOSUTINIB; CAVEOLIN 1; CD99 ANTIGEN; DASATINIB; PROTEIN KINASE INHIBITOR; SARCATINIB; SI 83; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; DRUG APPROVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; ONCOGENE SRC; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; SARCOMA; SIGNAL TRANSDUCTION;

EID: 84929882548     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3184     Document Type: Article

References (81)

1. Valkov A, Kilvaer TK, Sorbye SW, et al: The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Transl Med 9: 200, 2011.
2. Helman LJ and Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer 3: 685-694, 2003.
3. Coindre JM: New WHO classification of tumours of soft tissue and bone. Ann Pathol 32: S115-S116, 2012 (In French).
4. Klein MJ and Siegal GP: Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 125: 555-581, 2006.
5. de Bruijn DR, Allander SV, van Dijk AH, et al: The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 66: 9474-9482, 2006.
6. Sun Y, Gao D, Liu Y, Huang J, Lessnick S and Tanaka S: IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 25: 1042-1052, 2006.
7. Kashima TG, Gamage NG, Dirksen U, Gibbons CL, Ostlere SJ and Athanasou NA: Localized Ewing sarcoma of the tibia. Clin Sarcoma Res 3: 2, 2013.
8. Choi EY, Gardner JM, Lucas DR, McHugh JB and Patel RM: Ewing sarcoma. Semin Diagn Pathol 31: 39-47, 2014.
9. Kämmerer PW, Shabazfar N, Vorkhshori Makoie N, Moergel M and Al-Nawas B: Clinical, therapeutic and prognostic features of osteosarcoma of the jaws - experience of 36 cases. J Craniomaxillofac Surg 40: 541-548, 2012.
10. Steen S and Stephenson G: Current treatment of soft tissue sarcoma. Proc (Bayl Univ Med Cent) 21: 392-396, 2008.
11. von Mehren M, Randall RL, Benjamin RS, et al; National Comprehensive Cancer Network: Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw 12: 473-483, 2014.
12. Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med 353: 701-711, 2005.
13. Demicco EG, Maki RG, Lev DC and Lazar AJ: New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol 19: 170-180, 2012.
14. Byeon SE, Yi YS, Oh J, Yoo BC, Hong S and Cho JY: The role of Src kinase in macrophage-mediated inflammatory responses. Mediators Inflamm 2012: 512-926, 2012.
15. Levinson WE, Varmus HE, Garapin AC and Bishop JM: DNA of Rous sarcoma virus: its nature and significance. Science 175: 76-78, 1972.
16. Gojis O, Rudraraju B, Gudi M, et al: The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol 7: 83-89, 2010.
17. Boggon TJ and Eck MJ: Structure and regulation of Src family kinases. Oncogene 23: 7918-7927, 2004.
18. Guarino M: Src signaling in cancer invasion. J Cell Physiol 223: 14-26, 2010.
19. Hunter T and Sefton BM: Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 77: 1311-1315, 1980.
20. Roskoski R Jr: Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331: 1-14, 2005.
21. Bjorge JD, Jakymiw A and Fujita DJ: Selected glimpses into the activation and function of Src kinase. Oncogene 19: 5620-5635, 2000.
22. Zheng XM, Resnick RJ and Shalloway D: A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J 19: 964-978, 2000.
23. Cooper JA, Gould KL, Cartwright CA and Hunter T: Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science 231: 1431-1434, 1986.
24. Levin VA: Basis and importance of Src as a target in cancer. Cancer Treat Res 119: 89-119, 2004.
25. Sirvent A, Benistant C and Roche S: Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res 2: 357-371, 2012.
26. Cao M, Hou D, Liang H, et al: miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer 50: 1013-1024, 2014.
27. Roskoski R Jr: Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 324: 1155-1164, 2004.
28. Zhang S, Huang WC, Zhang L, et al: SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res 73: 5764-5774, 2013.
29. Gargalionis AN, Karamouzis MV and Papavassiliou AG: The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer 134: 2019-2029, 2014.
30. Je DW, O YM, Ji YG, Cho Y and Lee DH: The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas 43: 768-776, 2014.
31. Saini S, Majid S, Shahryari V, et al: Regulation of SRC Kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther 13: 1952-1963, 2014.
32. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004.
33. Kulbe H, Levinson NR, Balkwill F and Wilson JL: The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol 48: 489-496, 2004.
34. Bjorge JD, Pang A and Fujita DJ: Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 275: 41439-41446, 2000.
35. Dehm SM and Bonham K: SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 82: 263-274, 2004.
36. Mirmohammadsadegh A, Hassan M, Bardenheuer W, et al: STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 126: 2272-2280, 2006.
37. Niu G, Bowman T, Huang M, et al: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002.
38. Song L, Morris M, Bagui T, Lee FY, Jove R and Haura EB: Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66: 5542-5548, 2006.
39. Chen Z, Lee FY, Bhalla KN and Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 69: 1527-1533, 2006.
40. Schittenhelm MM, Shiraga S, Schroeder A, et al: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473-481, 2006.
41. Nakata Y, Tomkowicz B, Gewirtz AM and Ptasznik A: Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells. Blood 107: 4234-4239, 2006.
42. Chen YY, Malik M, Tomkowicz BE, Collman RG and Ptasznik A: BCR-ABL1 alters SDF-1alpha-mediated adhesive responses through the beta2 integrin LFA-1 in leukemia cells. Blood 111: 5182-5186, 2008.
43. Smolinska MJ, Page TH, Urbaniak AM, Mutch BE and Horwood NJ: Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. J Immunol 187: 6043-6051, 2011.
44. Lutz MP, Esser IB, Flossmann-Kast BB, et al: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243: 503-508, 1998.
45. Shor AC, Keschman EA, Lee FY, et al: Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67: 2800-2808, 2007.
46. Michels S, Trautmann M, Sievers E, et al: SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res 73: 2518-2528, 2013.
47. Díaz-Montero CM, Wygant JN and McIntyre BW: PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 42: 1491-1500, 2006.
48. Villacis RA, Silveira SM, Barros-Filho MC, et al: Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker. PLoS One 9: e102281, 2014.
49. Bai Y, Li J, Fang B, et al: Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72: 2501-2511, 2012.
50. Geng S, Wang X, Xu X, et al: Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1. Tumour Biol 35: 3087-3094, 2014.
51. Scully SP, Layfield LJ and Harrelson JM: Prognostic markers in chondrosarcoma: evaluation of cell proliferation and of regulators of the cell cycle. Sarcoma 1: 79-87, 1997.
52. Watanabe T, Tsuda M, Tanaka S, et al: Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res 7: 1582-1592, 2009.
53. Watanabe T, Tsuda M, Makino Y, et al: Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol Cancer Res 4: 499-510, 2006.
54. Mazzone M and Comoglio PM: The Met pathway: master switch and drug target in cancer progression. FASEB J 20: 1611-1621, 2006.
55. Spreafico A, Schenone S, Serchi T, et al: Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 22: 1560-1571, 2008.
56. Hingorani P, Zhang W, Gorlick R and Kolb EA: Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 15: 3416-3422, 2009.
57. Horng CT, Shieh PC, Tan TW, Yang WH and Tang CH: Paeonol suppresses chondrosarcoma metastasis through up-regulation of miR-141 by modulating PKCδ and c-Src signaling pathway. Int J Mol Sci 15: 11760-11772, 2014.
58. Wu CM, Li TM, Tan TW, Fong YC and Tang CH: Berberine Reduces the Metastasis of Chondrosarcoma by Modulating the α v β 3 Integrin and the PKC δ, c-Src, and AP-1 Signaling Pathways. Evid Based Complement Alternat Med 2013: 423164, 2013.
59. van Oosterwijk JG, van Ruler MA, Briaire-de Bruijn IH, et al: Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer 109: 1214-1222, 2013.
60. Guarino M: Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 39: 2153-2160, 2007.
61. Boyer B, Bourgeois Y and Poupon MF: Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 21: 2347-2356, 2002.
62. Huang WS, Wang RJ, Ding JL, et al: Caveolin-1: a novel biomarker for prostate cancer. Zhonghua Nan Ke Xue 18: 635-638, 2012 (In Chinese).
63. Mercier I and Lisanti MP: Caveolin-1 and breast cancer: a new clinical perspective. Adv Exp Med Biol 729: 83-94, 2012.
64. Cantiani L, Manara MC, Zucchini C, et al: Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 67: 7675-7685, 2007.
65. Manara MC, Bernard G, Lollini PL, et al: CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 17: 1910-1921, 2006.
66. Scotlandi K, Zuntini M, Manara MC, et al: CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 26: 6604-6618, 2007.
67. Abraham J, Chua YX, Glover JM, et al: An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochem Biophys Res Commun 426: 363-368, 2012.
68. Homsi J, Cubitt C and Daud A: The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 11: 91-100, 2007.
69. Creedon H and Brunton VG: Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog 17: 145-159, 2012.
70. Molina JR, Foster NR, Reungwetwattana T, et al: A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 85: 245-250, 2014.
71. Taylor JW, Dietrich J, Gerstner ER, et al: Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol: Nov 20, 2014 (Epub ahead of print).
72. Montero JC, Seoane S, Ocaña A and Pandiella A: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin Cancer Res 17: 5546-5552, 2011.
73. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, et al: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 69: 6216-6222, 2009.
74. Musumeci F, Schenone S, Brullo C and Botta M: An update on dual Src/Abl inhibitors. Future Med Chem 4: 799-822, 2012.
75. Girotti MR, Lopes F, Preece N, et al: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell 27: 85-96, 2015.
76. Rotert JV, Leupold J, Hohenberger P, Nowak K and Allgayer H: Src activity is increased in gastrointestinal stromal tumors - analysis of associations with clinical and other molecular tumor characteristics. J Surg Oncol 109: 597-605, 2014.
77. Qayyum T, McArdle PA, Lamb GW, et al: Expression and prognostic significance of Src family members in renal clear cell carcinoma. Br J Cancer 107: 856-863, 2012.
78. Sell H, Habich C and Eckel J: Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8: 709-716, 2012.
79. Spaeth E, Klopp A, Dembinski J, Andreeff M and Marini F: Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15: 730-738, 2008.
80. Hemmerle T, Probst P, Giovannoni L, Green AJ, Meyer T and Neri D: The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer 109: 1206-1213, 2013.
81. Spitaleri G, Berardi R, Pierantoni C, et al: Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol 139: 447-455, 2013.